The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the FDA has granted accelerated approval of Talvey (talquetamab-tgvs), a first-in-class bispecific antibody for the treatment of adult… read more.
Postmenopausal women who consume one or more sugar sweetened beverage daily appear to have a significantly higher risk of developing liver cancer and chronic liver disease than women… read more.
Among patients with resectable stage IIIA or IIIB NSCLC (non–small-cell lung cancer), those treated with neoadjuvant nivolumab plus chemotherapy have achieved a higher level of complete response and… read more.
Despite advances in surgery and chemotherapy, survival of people with certain types of ovarian cancer has not significantly changed in decades. That has meant that some ovarian cancer… read more.
Adjunctive therapy with atorvastatin appears to reduce the proportion of patients with lymphoma who are being treated with anthracyclines and who also develop cardiac dysfunction. The findings were… read more.
A study of more than 50,000 women found that continued breast cancer screening after age 70 was associated with a greater incidence of cancer that likely would not… read more.
Taiho Pharmaceutical announced that its partner Servier, has won European regulatory approval for Lonsurf (trifluridine + tipiracil) in combination with bevacizumab for the third-line treatment of metastatic colorectal… read more.
More than 4 out of 5 older women survivors of colorectal cancer may be experiencing a range of gastrointestinal symptoms many years after being diagnosed and treated, a… read more.
An interim safety analysis of the first randomised controlled trial of its kind involving over 80,000 Swedish women published in The Lancet Oncology journal, finds artificial intelligence (AI)-supported mammography analysis… read more.
GSK plc announced that the FDA has approved Jemperli (dostarlimab) in combination with carboplatin and paclitaxel, followed by Jemperli as a single agent for the treatment of adult… read more.
Gilead Sciences, Inc. announced that the European Commission (EC) approved Trodelvy (sacituzumab govitecan) as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor… read more.
Findings from an aaccepted manuscript published in the American Journal of Roentgenology (AJR) suggest that for patients with dense breasts undergoing screening in the incidence setting, a commercial AI tool did… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
